SHP Share Price

Open 4787.00 Change Price %
High 4887.00 1 Day 17.25 0.36
Low 4785.00 1 Week 250.25 5.48
Close 4818.25 1 Month 425.25 9.68
Volume 1121745 1 Year 999.25 26.17
52 Week High 5377.00
52 Week Low 2707.19
SHP Important Levels
Resistance 2 4912.80
Resistance 1 4873.84
Pivot 4830.08
Support 1 4762.66
Support 2 4723.70
LON UK Most Active Stocks
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LGO 0.11 -8.33%
LGO 0.11 -8.33%
LGO 0.11 -8.33%
LLOY 67.11 -0.36%
OTC 0.02 0.00%
OTC 0.02 0.00%
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
BAF 89.80 83.27%
BAF 89.80 83.27%
BAF 89.80 83.27%
BAC 24.71 76.50%
BAC 24.71 76.50%
BAC 24.71 76.50%
MES 0.28 75.00%
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
NRRP 4.45 -53.16%
BHR 0.02 -33.33%

Shire PLC (LON: SHP)

SHP Technical Analysis 4
As on 21st Feb 2017 SHP Share Price closed @ 4818.25 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4615.07 & Strong Buy for SHORT-TERM with Stoploss of 4568.83 we also expect STOCK to react on Following IMPORTANT LEVELS.
SHP Target for February
1st Target up-side 4751.71
2nd Target up-side 4995.43
3rd Target up-side 5239.14
1st Target down-side 4056.29
2nd Target down-side 3812.57
3rd Target down-side 3568.86
SHP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website
SHP Address
5 Riverwalk
Citywest Business Campus
Dublin, 24
Phone: 353 1 429 7700
SHP Latest News
Is this small-cap value stock the next Shire plc?   Motley Fool UK   - 21st Feb 17
Shire PLC 5% Potential Decrease Indicated by HSBC   DirectorsTalk Interviews   - 21st Feb 17
Stock Price of Shire plc (SHPG) Increases 5.51%   Highland Mirror   - 21st Feb 17
Why Shire's 2017 Guidance Is Encouraging And Should Reassure Investors   Seeking Alpha   - 20th Feb 17
Shire PLC 4Q Earnings, Revenue Beat Street (SHPG)   Investopedia   - 18th Feb 17
Shire PLC 39.1% Potential Upside Indicated by Jefferies International   DirectorsTalk Interviews   - 17th Feb 17
Drugs-crazed shoot-out: which investment is best out of Astra, Glaxo and Shire?   Proactive Investors UK   - 17th Feb 17
Earnings Reaction History: Shire plc, 33.3% Follow-Through Indicator, 2.4 ...   Nasdaq   - 16th Feb 17
Radius Health (RDUS) Stock: Gaining On Shire PLC (SHPG) Interest   CNA Finance (press release)   - 15th Feb 17
What To Expect At Shire's FY 2016 Results   Seeking Alpha   - 07th Feb 17
Interactive Technical Analysis Chart Shire PLC ( SHP LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Shire PLC
SHP Business Profile
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.